# Shattuck Labs, Inc.: financial statements, quarterly

STTK · Nasdaq · CIK 1680367 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/sttk.md) · [Financials](/companies/sttk/financials.md) · [Filings](/companies/sttk/filings.md) · [Insiders](/companies/sttk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/sttk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.7](/filings/0001680367-24-000053.md) | [0.7 d](/filings/0001680367-25-000012.md) | [1.1](/filings/0001680367-25-000034.md) | [1.6](/filings/0001680367-25-000046.md) | [3.0](/filings/0001680367-25-000057.md) | [0.0 d](/filings/0001628280-26-014989.md) | [0.0](/filings/0001628280-26-031661.md) | [0.0](/filings/0001628280-26-055483.md) | [1.0](/filings/0001680367-25-000057.md) | [0.0 d](/filings/0001628280-26-014989.md) | [0.0](/filings/0001628280-26-031661.md) | [0.0](/filings/0001628280-26-055483.md) |
| Research and development | $m | [24.2](/filings/0001680367-24-000053.md) | [15.2 d](/filings/0001680367-25-000012.md) | [16.3](/filings/0001680367-25-000034.md) | [19.2](/filings/0001680367-25-000046.md) | [16.3](/filings/0001680367-25-000057.md) | [15.4 d](/filings/0001628280-26-014989.md) | [9.9](/filings/0001628280-26-031661.md) | [8.7](/filings/0001628280-26-055483.md) | [7.6](/filings/0001680367-25-000057.md) | [9.1 d](/filings/0001628280-26-014989.md) | [10.9](/filings/0001628280-26-031661.md) | [11.7](/filings/0001628280-26-055483.md) |
| Operating income | $m | [(28.6)](/filings/0001680367-24-000053.md) | [(19.0) d](/filings/0001680367-25-000012.md) | [(20.0)](/filings/0001680367-25-000034.md) | [(23.0)](/filings/0001680367-25-000046.md) | [(17.9)](/filings/0001680367-25-000057.md) | [(19.6) d](/filings/0001628280-26-014989.md) | [(14.4)](/filings/0001628280-26-031661.md) | [(13.0)](/filings/0001628280-26-055483.md) | [(10.7)](/filings/0001680367-25-000057.md) | [(13.4) d](/filings/0001628280-26-014989.md) | [(15.5)](/filings/0001628280-26-031661.md) | [(16.2)](/filings/0001628280-26-055483.md) |
| Net income | $m | [(27.5)](/filings/0001680367-24-000053.md) | [(17.7) d](/filings/0001680367-25-000012.md) | [(18.5)](/filings/0001680367-25-000057.md) | [(21.6)](/filings/0001680367-25-000057.md) | [(16.7)](/filings/0001680367-25-000057.md) | [(18.7) d](/filings/0001628280-26-014989.md) | [(13.7)](/filings/0001628280-26-055483.md) | [(12.5)](/filings/0001628280-26-055483.md) | [(10.1)](/filings/0001680367-25-000057.md) | [(12.6) d](/filings/0001628280-26-014989.md) | [(14.8)](/filings/0001628280-26-055483.md) | [(15.2)](/filings/0001628280-26-055483.md) |
| Diluted EPS | $ per share | [(0.65)](/filings/0001680367-24-000053.md) | not reported | [(0.37)](/filings/0001680367-25-000034.md) | [(0.42)](/filings/0001680367-25-000046.md) | [(0.33)](/filings/0001680367-25-000057.md) | not reported | [(0.27)](/filings/0001628280-26-031661.md) | [(0.24)](/filings/0001628280-26-055483.md) | [(0.14)](/filings/0001680367-25-000057.md) | not reported | [(0.13)](/filings/0001628280-26-031661.md) | [(0.12)](/filings/0001628280-26-055483.md) |
| Basic EPS | $ per share | [(0.65)](/filings/0001680367-24-000053.md) | not reported | [(0.37)](/filings/0001680367-25-000034.md) | [(0.42)](/filings/0001680367-25-000046.md) | [(0.33)](/filings/0001680367-25-000057.md) | not reported | [(0.27)](/filings/0001628280-26-031661.md) | [(0.24)](/filings/0001628280-26-055483.md) | [(0.14)](/filings/0001680367-25-000057.md) | not reported | [(0.13)](/filings/0001628280-26-031661.md) | [(0.12)](/filings/0001628280-26-055483.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [40.6](/filings/0001680367-23-000062.md) | [126](/filings/0001680367-25-000012.md) | [76.0](/filings/0001680367-24-000025.md) | [60.7](/filings/0001680367-24-000040.md) | [43.8](/filings/0001680367-24-000053.md) | [57.4](/filings/0001628280-26-014989.md) | [60.9](/filings/0001680367-25-000034.md) | [50.5](/filings/0001680367-25-000046.md) | [42.5](/filings/0001680367-25-000057.md) | [54.2](/filings/0001628280-26-055483.md) | [90.4](/filings/0001628280-26-031661.md) | [63.3](/filings/0001628280-26-055483.md) |
| Current assets | $m | [113](/filings/0001680367-23-000062.md) | [143](/filings/0001680367-25-000012.md) | [131](/filings/0001680367-24-000025.md) | [114](/filings/0001680367-24-000040.md) | [98.7](/filings/0001680367-24-000053.md) | [79.2](/filings/0001628280-26-014989.md) | [66.4](/filings/0001680367-25-000034.md) | [54.7](/filings/0001680367-25-000046.md) | [90.7](/filings/0001680367-25-000057.md) | [82.5](/filings/0001628280-26-055483.md) | [93.8](/filings/0001628280-26-031661.md) | [213](/filings/0001628280-26-055483.md) |
| Total assets | $m | [130](/filings/0001680367-23-000062.md) | [160](/filings/0001680367-25-000012.md) | [146](/filings/0001680367-24-000025.md) | [129](/filings/0001680367-24-000040.md) | [112](/filings/0001680367-24-000053.md) | [91.0](/filings/0001628280-26-014989.md) | [77.2](/filings/0001680367-25-000034.md) | [64.4](/filings/0001680367-25-000046.md) | [100](/filings/0001680367-25-000057.md) | [91.0](/filings/0001628280-26-055483.md) | [102](/filings/0001628280-26-031661.md) | [221](/filings/0001628280-26-055483.md) |
| Current liabilities | $m | [14.1](/filings/0001680367-23-000062.md) | [11.5](/filings/0001680367-25-000012.md) | [14.3](/filings/0001680367-24-000025.md) | [15.0](/filings/0001680367-24-000040.md) | [12.4](/filings/0001680367-24-000053.md) | [8.9](/filings/0001628280-26-014989.md) | [7.3](/filings/0001680367-25-000034.md) | [5.3](/filings/0001680367-25-000046.md) | [5.3](/filings/0001680367-25-000057.md) | [7.1](/filings/0001628280-26-055483.md) | [4.2](/filings/0001628280-26-031661.md) | [7.7](/filings/0001628280-26-055483.md) |
| Total liabilities | $m | [17.7](/filings/0001680367-23-000062.md) | [14.9](/filings/0001680367-25-000012.md) | [17.5](/filings/0001680367-24-000025.md) | [18.0](/filings/0001680367-24-000040.md) | [15.1](/filings/0001680367-24-000053.md) | [11.4](/filings/0001628280-26-014989.md) | [9.6](/filings/0001680367-25-000034.md) | [7.4](/filings/0001680367-25-000046.md) | [7.1](/filings/0001680367-25-000057.md) | [8.6](/filings/0001628280-26-055483.md) | [6.3](/filings/0001628280-26-031661.md) | [9.5](/filings/0001628280-26-055483.md) |
| Shareholders' equity | $m | [113](/filings/0001680367-24-000053.md) | [145](/filings/0001628280-26-014989.md) | [129](/filings/0001680367-25-000057.md) | [111](/filings/0001680367-25-000057.md) | [96.6](/filings/0001680367-25-000057.md) | [79.6](/filings/0001628280-26-055483.md) | [67.6](/filings/0001628280-26-055483.md) | [57.0](/filings/0001628280-26-055483.md) | [93.2](/filings/0001680367-25-000057.md) | [82.4](/filings/0001628280-26-055483.md) | [95.8](/filings/0001628280-26-055483.md) | [211](/filings/0001628280-26-055483.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(16.7) d](/filings/0001680367-24-000053.md) | [(19.4) d](/filings/0001680367-25-000012.md) | [(16.2)](/filings/0001680367-25-000034.md) | [(10.9) d](/filings/0001680367-25-000046.md) | [(16.1) d](/filings/0001680367-25-000057.md) | [(17.4) d](/filings/0001628280-26-014989.md) | [(12.0)](/filings/0001628280-26-031661.md) | [(10.4) d](/filings/0001628280-26-055483.md) | [(8.9) d](/filings/0001680367-25-000057.md) | [(8.5) d](/filings/0001628280-26-014989.md) | [(13.4)](/filings/0001628280-26-031661.md) | [(10.2) d](/filings/0001628280-26-055483.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001680367-24-000053.md) | [0.0 d](/filings/0001680367-25-000012.md) | [0.0](/filings/0001680367-24-000025.md) | [0.0 d](/filings/0001680367-25-000046.md) | [0.0 d](/filings/0001680367-25-000057.md) | [0.0 d](/filings/0001628280-26-014989.md) | not reported | not reported | [0.1 d](/filings/0001680367-25-000057.md) | [0.0 d](/filings/0001628280-26-014989.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [42.4](/filings/0001680367-23-000062.md) | [42.4](/filings/0001680367-24-000025.md) | [42.5](/filings/0001680367-24-000040.md) | [42.5](/filings/0001680367-24-000053.md) | [50.6](/filings/0001680367-25-000034.md) | [50.8](/filings/0001680367-25-000046.md) | [50.8](/filings/0001680367-25-000057.md) | [51.0](/filings/0001628280-26-031661.md) | [51.0](/filings/0001628280-26-055483.md) | [72.2](/filings/0001680367-25-000057.md) | [112](/filings/0001628280-26-031661.md) | [130](/filings/0001628280-26-055483.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 100,363,253 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001628280-26-055483.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.